Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's financial performance was better than expected, with efficient resource management and strong cash reserves. The Q&A session highlighted positive trial developments, such as strong patient enrollment and promising safety profiles, despite some management evasiveness on specific data updates. These factors, combined with the company's market cap, suggest a positive stock price movement within the 2% to 8% range.
Key Financial Performance
Net Cash Used in Operating and Investing Activities $136.7 million, favorable to guidance range of $148 million to $161 million.
Net Loss $147 million, favorable to guidance range of $153 million to $171 million.
Cash Position $621 million in cash, cash equivalents, and restricted cash, favorable to guidance of $600 million.
Ordinary Shares Outstanding Approximately 53.7 million shares.
Debt Zero debt.
Estimated Net Cash Used in Operating and Investing Activities for 2024 Between $208 million and $225 million.
Estimated Net Loss for 2024 $229 million to $255 million, which includes an estimated $51 million of non-cash share-based compensation expense.
Estimated Cash Position at Year-End 2024 Approximately $405 million in cash, cash equivalents, and restricted cash.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PRX12: PRX12 is a next-generation investigational treatment for Alzheimer's disease, designed for once monthly, at-home subcutaneous administration, aiming to be best-in-class.
Birtamimab: Birtamimab is in a confirmatory Phase 3 trial for MAYO Stage IV AL Amyloidosis, with top-line results expected between Q4 2024 and Q2 2025.
Prasinezumab: Prasinezumab is in a Phase 2b trial for Parkinson's disease, with top-line data expected later this year.
NNC6019: NNC6019 is in a Phase 2 trial for ATTR cardiomyopathy, with results expected in the first half of next year.
Market for Birtamimab: Prothena plans to independently commercialize Birtamimab, targeting over 20,000 patients with MAYO Stage IV AL Amyloidosis across major markets.
Cash Position: Prothena ended 2023 with a strong cash position of $621 million, allowing for continued investment in clinical programs.
Financial Performance: Net cash used in operating and investing activities was $136.7 million, better than the guidance range of $148 million to $161 million.
Strategic Partnerships: BMS opted into global rights for BMS 986446 (formerly PRX005) for $55 million, enhancing Prothena's financial position.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is subject to regulatory scrutiny and must comply with FDA requirements, particularly regarding the confirmatory Phase 3 AFFIRM AL clinical trial for Birtamimab, which has a pre-agreed significance level for approval.
Clinical Trial Risks: The success of Prothena's programs, including Birtamimab, PRX12, Prasinezumab, and NNC6019, is contingent on the outcomes of ongoing clinical trials, which carry inherent risks of failure or delays.
Market Competition: Prothena faces competitive pressures in the biotechnology sector, particularly in the development of therapies for neurodegenerative diseases, which may impact market share and pricing.
Financial Risks: The company anticipates a net cash usage of $208 million to $225 million in 2024, with a projected net loss of $229 million to $255 million, which could affect financial stability if revenues do not meet expectations.
Supply Chain Challenges: The company may encounter supply chain challenges that could impact the production and distribution of its therapeutic candidates, particularly as it prepares for potential commercialization.
Economic Factors: Economic conditions may affect funding availability and investment in biotechnology, which could impact Prothena's ability to finance its operations and clinical programs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Clinical Programs: Prothena has a robust portfolio of therapeutic drug candidates targeting neurodegenerative and rare peripheral amyloid diseases, including four wholly-owned programs and five partnered programs.
Birtamimab Program: Birtamimab is in a confirmatory Phase 3 trial (AFFIRM AL) for MAYO Stage IV AL Amyloidosis, with top-line results expected between Q4 2024 and Q2 2025.
PRX12 Program: PRX12 is in a Phase 1 trial for Alzheimer's disease, designed to establish a best-in-class profile with a once-monthly subcutaneous treatment.
Prasinezumab Program: Prasinezumab is in a Phase 2b trial for Parkinson's disease, with top-line data expected later in 2024.
NNC6019 Program: NNC6019 is in a Phase 2 trial for ATTR cardiomyopathy, with results expected in the first half of 2025.
2024 Financial Guidance: Prothena expects net cash used in operating and investing activities to be between $208 million and $225 million, with an estimated net loss of $229 million to $255 million.
Cash Position: Prothena anticipates ending 2024 with approximately $405 million in cash, cash equivalents, and restricted cash.
2023 Financial Performance: Prothena reported a net cash used of $136.7 million, better than the guidance range of $148 million to $161 million, and a net loss of $147 million, favorable to the guidance of $153 million to $171 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: Prothena Corporation has not announced any share buyback program or dividend program during the call. The focus remains on advancing clinical programs and maintaining a strong cash position.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you provide more clarity on the patient enrollment in ascent 2, specifically what patient or what cohorts have been enrolled both A and B in terms of which doses?
A:Enrollment is very strong in our PRX12 Signal trial. The Monitoring Board has authorized a 400 mg and proceeding cohort.
Q:Could you talk about the six-month open-label extension and what do you hope to learn from that? Will patients on low doses switch to high doses?
A:Each patient within each cohort enrolls in an open-label extension for six months. We are capturing both safety and tolerability.
Q:How do you reconcile the comparable ARIA rates between the 70 mg dose of 012 and placebo?
A:There is evidence of an exposure response relationship between amyloid reduction and ARIA rates, which is molecule dependent.
Q:Is the comment on ARIA being consistent with placebo true for both cohort A and cohort B patients?
A:With the A cohort, we've seen encouraging reduction in amyloid beta and ARIA rates consistent with placebo.
Q:Can you talk about the rationale for including the 45-mg dose in ascent 2 which was not tested in ascent 1?
A:Evaluating dose levels from 45 mg to 400 mg provides a comprehensive overview of the exposure response relationship.
Q:When you say consistent with placebo, was there actually one case of ARIA in the placebo?
A:The ARIA rates were consistent with placebo, indicating a therapeutic index that allows for dose escalation.
Q:How do we think about the PUC, the C-Max and relative fractional occupancy in relation to PRX12 development?
A:We need to be informed by data from multiple dose level cohorts from our ongoing Phase 1 trial to better characterize the relationship.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific details of patient cohorts enrolled in ascent 2, as well as the exact ARIA rates in the placebo group.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AL trial
APOε
Amyloidosis
IV
MAYO Stage
MDS UPDRS
PADOVA trial
Part III
Phase trial
Slide
UPDRS Part
antibody treatment
carrier
case
course
difference
dose level
drug
enrollment
entirety population
exposure response
group
index
label extension
level cohort
line result
mg
milligram
month
participant
patient MAYO
perspective
placebo
point
rate
respect
response relationship
trial patient
PRTA Transcript
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings call reflects a mixed sentiment. Financial performance shows prudent capital utilization but also a significant net loss. The Q&A highlights promising developments in product trials and partnerships, but also reveals management's reluctance to provide detailed guidance, creating uncertainty. The share redemption plan indicates potential shareholder value but lacks immediate impact. Overall, the stock is likely to remain neutral, with no strong catalysts for significant movement. The market cap suggests moderate sensitivity to these factors.
Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Call Transcript
Unknown2-21
Earnings call shows EPS and net loss near lower guidance, no share repurchase, and uncertainties in AL amyloidosis treatment. Q&A reveals lack of specifics on critical issues and unclear management responses, indicating potential risks. Although management is optimistic about birtamimab's market potential, the financial metrics and lack of guidance clarity suggest a negative sentiment. Given the small-cap nature of the company, this could lead to a stock price decline of -2% to -8%.
Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript
Positive2-16
The company's financial performance was better than expected, with efficient resource management and strong cash reserves. The Q&A session highlighted positive trial developments, such as strong patient enrollment and promising safety profiles, despite some management evasiveness on specific data updates. These factors, combined with the company's market cap, suggest a positive stock price movement within the 2% to 8% range.
Prothena Corporation plc (PRTA) Q4 2022 Earnings Call Transcript
Neutral2-24
PRTA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
